New 3β,6β-dihydroxy and 3β,5α,6β-trihydroxy sterols from marine bryozoan Bugula neritina in South China Sea and their cytotoxicity

Tian, Xiangrong; Tang, Hai‐Feng; Li, Yushan; Lin, Hou-Wen; Fan, Xiao-Pei; Feng, Juntao; Zhang, Xing

doi:10.1016/j.phytol.2014.03.010

Cited by 9 publications

(6 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other two new sterols ((22E)-cholest-4,22-diene-3β,6β-diol and (23S,24R)-dimethylcholest-7-ene-3β, 5α,6β-triol), a sterol reported for the first time from natural sources ((22E,24S)-24-methylcholest-4,22-diene-3β,6β-diol), a known steroid glycoside, and six known sterols were also isolated from B. neritina in the same region. All compounds were inactive against human tumor cell lines Hep-G2, NCI-H460, and SGC-7901 (IC 50 > 36.6 μM) [115].…”

Section: Cytotoxic Compounds From Marine Bryozoans With Activity Amentioning

confidence: 99%

The Phylum Bryozoa as a Promising Source of Anticancer Drugs

Figuerola

Ávila

2019

Marine Drugs

View full text Add to dashboard Cite

Recent advances in sampling and novel techniques in drug synthesis and isolation have promoted the discovery of anticancer agents from marine organisms to combat this major threat to public health worldwide. Bryozoans, which are filter-feeding, aquatic invertebrates often characterized by a calcified skeleton, are an excellent source of pharmacologically interesting compounds including well-known chemical classes such as alkaloids and polyketides. This review covers the literature for secondary metabolites isolated from marine cheilostome and ctenostome bryozoans that have shown potential as cancer drugs. Moreover, we highlight examples such as bryostatins, the most known class of marine-derived compounds from this animal phylum, which are advancing through anticancer clinical trials due to their low toxicity and antineoplastic activity. The bryozoan antitumor compounds discovered until now show a wide range of chemical diversity and biological activities. Therefore, more research focusing on the isolation of secondary metabolites with potential anticancer properties from bryozoans and other overlooked taxa covering wider geographic areas is needed for an efficient bioprospecting of natural products.

show abstract

Section: Cytotoxic Compounds From Marine Bryozoans With Activity Amentioning

confidence: 99%

The Phylum Bryozoa as a Promising Source of Anticancer Drugs

Figuerola

Ávila

2019

Marine Drugs

View full text Add to dashboard Cite

show abstract

“…Other two new sterols ((22E)cholest-4,22-diene-3β,6β-diol (1) and (23S,24R)-dimethylcholest-7-ene-3β, 5α,6β-triol (3)), a sterol reported for the first time from natural sources ((22E,24S)-24-methylcholest-4,22-diene-3β,6β-diol (2)), a known steroid glycoside (4) and six known sterols (5)(6)(7)(8)(9)(10) were also isolated from B. neritina in the same region. While all compounds were evaluated for their cytotoxicity against human tumour cell lines HepG2, NCI-H460 and SGC7901, only 1, 2 and 5 displayed inhibition against HepG2 cancer cell line [91].…”

Section: Sterolsmentioning

confidence: 99%

The Understudied Phylum Bryozoa as a Promising Source of Anticancer Drugs

Figuerola¹,

Ávila²

2019

Preprint

View full text Add to dashboard Cite

Recent advances in sampling and novel techniques in drug synthesis and isolation have promoted the discovery of anticancer agents from marine organisms to combat this major threat to public health worldwide. Bryozoans, filter-feeding, sessile aquatic invertebrates often characterized by a calcified skeleton, are an excellent source of pharmacologically interesting compounds including well-known chemical classes such as alkaloids and polyketides. This review covers the literature for secondary metabolites isolated from marine cheilostome and ctenostome bryozoans that have shown potential as cancer drugs. Moreover, we highlight examples such as bryostatins, the most known class of marine-derived compounds from this animal phylum, which is advancing through anticancer clinical trials due to their low toxicity and antineoplastic activity. The bryozoan antitumour compounds discovered until now show a wide range of chemical diversity and biological activities. Therefore, more research focusing on the isolation of secondary metabolites with potential anticancer properties from bryozoans and other overlooked taxa covering wider geographic areas is needed for an efficient bioprospecting of natural products.

show abstract

“…Cytotoxicity evaluations of those sterols demonstrated that they are inactive constituents against tumor cell lines HepG2, NCI-H460 and SGC7901 [44]. SAR analysis suggested that the double bond at C-7 in the nucleus plays an important role in the lower cytotoxicity for this type of sterol [45].…”

Section: Sterols From Marine Bryozoansmentioning

confidence: 99%

“…The sterol with the similar side chain has only been prepared by chemical synthesis [46]. Two new sterols (42-43) with nucleus of E are also discovered from B. neritina [44]. Compounds 42 and 43 showed selective growth inhibition against the HepG2 cancer cell line with IC 50 values of 36.5 and 52.1 μM, respectively, while they were inactive against NCI-H460 and SGC7801 cell lines.…”

Section: Sterols From Marine Bryozoansmentioning

confidence: 99%

Review of Bioactive Secondary Metabolites from Marine Bryozoans in the Progress of New Drugs Discovery

et al. 2018

View full text Add to dashboard Cite

Marine bryozoans play an important role for the discovery of novel bioactive compounds among marine organisms. In this review, we summarize 164 new secondary metabolites including macrocyclic lactones, sterols, alkaloids, sphingolipids and so forth from 24 marine bryozoans in the last two decades. The structural features, bioactivity, structure-activity relationship, mechanism and strategies to address the resupply of these scarce secondary metabolites are discussed. The structural and bioactive diversity of the secondary metabolites from marine bryozoans indicated the possibility of using these compounds, especially bryostatin 1 (1), bryostatin analog (BA1), alkaloids (50, 53, 127-128 and 134-139), sphingolipids sulfates (148 and 149) and sulfur-containing aromatic compound (160), as the starting points for new drug discovery.

show abstract

New 3β,6β-dihydroxy and 3β,5α,6β-trihydroxy sterols from marine bryozoan Bugula neritina in South China Sea and their cytotoxicity

Cited by 9 publications

References 25 publications

The Phylum Bryozoa as a Promising Source of Anticancer Drugs

The Phylum Bryozoa as a Promising Source of Anticancer Drugs

The Understudied Phylum Bryozoa as a Promising Source of Anticancer Drugs

Review of Bioactive Secondary Metabolites from Marine Bryozoans in the Progress of New Drugs Discovery

Contact Info

Product

Resources

About